RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 157 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.96 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,249 | +126.8% | 7,092 | +121.4% | 0.00% | – |
| Q2 2023 | $23,924 | +16.7% | 3,203 | +4.2% | 0.00% | – |
| Q1 2023 | $20,502 | -31.7% | 3,074 | -22.8% | 0.00% | – |
| Q4 2022 | $30,000 | -16.7% | 3,984 | +17.7% | 0.00% | – |
| Q3 2022 | $36,000 | +63.6% | 3,385 | +23.5% | 0.00% | – |
| Q2 2022 | $22,000 | -18.5% | 2,740 | -28.0% | 0.00% | – |
| Q1 2022 | $27,000 | -50.0% | 3,808 | +19.9% | 0.00% | – |
| Q4 2021 | $54,000 | 0.0% | 3,175 | +32.6% | 0.00% | – |
| Q3 2021 | $54,000 | -21.7% | 2,395 | +26.7% | 0.00% | – |
| Q2 2021 | $69,000 | – | 1,890 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $77,730,340 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $44,380,166 | 32.86% |
| MV Management XI, L.L.C. | 1,971,908 | $14,730,153 | 25.77% |
| MIC Capital Management UK LLP | 8,451,758 | $63,134,635 | 12.84% |
| Yong Rong (HK) Asset Management Ltd | 1,174,200 | $8,772 | 3.85% |
| ArchPoint Investors | 1,114,626 | $8,326,256 | 3.22% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,711,148 | $20,252,276 | 0.70% |
| HARVARD MANAGEMENT CO INC | 882,129 | $6,590 | 0.65% |
| Diametric Capital, LP | 119,906 | $895,698 | 0.40% |
| Lingotto Investment Management LLP | 775,077 | $5,789,825 | 0.37% |